Sanofi and Regeneron’s once close relationship has ... refocus Sanofi since taking the helm – for example axing R&D in diabetes, once its cash-cow category, and cardiovascular – in order ...

Regeneron and Alnylam are to research treatments ... and is associated with increased risk of problems such as diabetes, heart attacks, and strokes. Drugs that get to market could generate ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... which have the potential to treat more ...